Related Experiment Video

Updated: Aug 7, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Protein kinase C inhibitors as novel anticancer drugs

P G Goekjian1, M R Jirousek

  • 1Laboratoire Chimie Organique II/UMR 5622, Universite Claude Bernard Lyon 1; Bat. 308-CPE, 3 Rue Victor Grignard, 69622 Villeurbanne Cedex, France. goekjian@univ-lyon1.fr

Expert Opinion on Investigational Drugs
|January 5, 2002
PubMed

Insights

Protein kinase C (PKC) inhibitors show promise for cancer treatment, with several advancing to late-stage development. Further research into concurrent inhibition of multiple PKC isoforms may improve clinical outcomes.

Area of Science:

  • Molecular Biology
  • Oncology
  • Pharmacology

Background:

  • Protein kinase C (PKC) isoforms play complex roles in cancer-related signaling pathways, including cell cycle regulation, apoptosis, angiogenesis, and drug efflux.
  • Understanding these intricate roles is crucial for interpreting clinical data from PKC inhibitors.

Purpose of the Study:

  • To review the role of PKC isoforms in cancer signaling.
  • To analyze the clinical results of various PKC inhibitors.
  • To assess the potential of PKC inhibition as a cancer therapy.

Main Methods:

  • Review of scientific literature on PKC isoforms and their functions in cancer.
  • Analysis of clinical trial data for selected PKC inhibitors, including midostaurin, UCN-01, and others.
  • Evaluation of inhibitor selectivity for PKC isoforms and kinases.

Main Results:

  • Several PKC inhibitors, such as midostaurin and LY 333531, have reached later stages of clinical development.
  • Initial safety and efficacy data for these inhibitors are encouraging.
  • PKC inhibitors exhibit varying selectivity profiles for different PKC isoforms and kinases.

Conclusions:

  • The full therapeutic potential of PKC inhibition in cancer treatment is yet to be realized.
  • Targeting multiple PKC isoforms concurrently may offer improved clinical benefits due to their interconnected roles.
  • Further investigation into selective and multi-isoform PKC inhibitors is warranted.

More Related Videos

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: